Immunic is advancing its Nurr1 program beyond multiple sclerosis’s inflammation ceiling, with Phase III activity expected to evaluate vidofludimus calcium. The development plan centers on whether pairing DHODH inhibition with direct neuroprotective effects can slow MS progression. Vidofludimus calcium is positioned as a test of a dual-mechanism concept—combining immune modulation through DHODH inhibition (a dihydroorotate dehydrogenase pathway target) with additional neuroprotective activity. If the Phase III readout supports the hypothesis, it could shift treatment expectations from primarily inflammatory control toward disease-course impact. The near-term industry watch item will be whether the Phase III endpoint strategy supports progression-relevant claims, particularly given the competitive pressure in MS to demonstrate durable outcomes beyond relapse reduction.